<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00950573</url>
  </required_header>
  <id_info>
    <org_study_id>NOCTX</org_study_id>
    <nct_id>NCT00950573</nct_id>
  </id_info>
  <brief_title>Arterial Calcifications in Nocturnal Hemodialysis and Renal Transplantation Versus Conventional Dialysis</brief_title>
  <acronym>NOCTX</acronym>
  <official_title>Is Progression of Arteriosclerosis in ESRD Patients Inhibited by Nocturnal Hemodialysis or Renal Transplantation?</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dianet Dialysis Centers</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Dianet Dialysis Centers</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Objective:

        1. To assess whether nocturnal hemodialysis and renal transplantation are associated with
           less progression of coronary arterial calcification, compared with conventional
           hemodialysis and peritoneal dialysis;

        2. To identify the risk factors for coronary arterial calcification in dialysis and
           transplant patients, and to assess a possible interaction with treatment modality.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To assess whether nocturnal hemodialysis and renal transplantation are associated with less
      progression of coronary arterial calcification, compared with conventional hemodialysis and
      peritoneal dialysis; To identify the risk factors for coronary arterial calcification in
      dialysis and transplant patients, and to assess a possible interaction with treatment
      modality.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2010</start_date>
  <completion_date type="Actual">December 12, 2018</completion_date>
  <primary_completion_date type="Actual">December 12, 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Change in coronary artery calcification score</measure>
    <time_frame>3 yrs</time_frame>
    <description>The coronary artery calcification score is measured in Agatston units or cubic millimeters and ranges from zero to theoretically infite. This coronary artery calcicifcation score is a total score for all coronary arteries. A higher score, and thus a higher increase in coronary artery calcification score, therefore represents a worse outcome.</description>
  </primary_outcome>
  <number_of_groups>4</number_of_groups>
  <enrollment type="Actual">184</enrollment>
  <condition>Kidney Disease</condition>
  <arm_group>
    <arm_group_label>hemodialysis</arm_group_label>
    <description>patients treated with conventional hemodialysis</description>
  </arm_group>
  <arm_group>
    <arm_group_label>peritoneal dialysis</arm_group_label>
    <description>patients treated with peritoneal dialysis</description>
  </arm_group>
  <arm_group>
    <arm_group_label>nocturnal hemodialysis</arm_group_label>
    <description>patients treated with frequent nocturnal hemodialysis</description>
  </arm_group>
  <arm_group>
    <arm_group_label>kidney transplantation</arm_group_label>
    <description>patients treated with renal transplantation</description>
  </arm_group>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      1x 4,5 ml citrate plasma

      1x 10 ml EDTA plasma
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with ESRD
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  ESRD

          -  current age &gt; 18 and &lt; 75 yr

          -  ability to understand the study procedures

          -  willingness to provide written informed consent

        Exclusion Criteria:

          -  life expectancy &lt; 3 months

          -  claustrophobia

          -  allergy to iodinated contrast

          -  treatment incompliance, i.e. non-adherence to dialysis regimens and drug use

          -  GFR &lt; 30 ml/min (according to MDRD formula) in renal transplant patients

          -  pregnancy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Brigit van Jaarsveld, MD, PHD</last_name>
    <role>Principal Investigator</role>
    <affiliation>VU University Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Dianet Dialysis Centers</name>
      <address>
        <city>Utrecht</city>
        <zip>3524BN</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Medical Center Utrecht</name>
      <address>
        <city>Utrecht</city>
        <zip>3584 CX</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>December 2018</verification_date>
  <study_first_submitted>July 31, 2009</study_first_submitted>
  <study_first_submitted_qc>July 31, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 3, 2009</study_first_posted>
  <last_update_submitted>December 17, 2018</last_update_submitted>
  <last_update_submitted_qc>December 17, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">December 19, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>cardiovascular disease</keyword>
  <keyword>endstage renal disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

